文献速递眼底病与葡萄膜炎

Sarilumab治疗眼后段非感染性葡萄膜炎的2期SATURN研究

Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.
PubMed 文献 · Ophthalmology · 2018-10-11

第16周主要终点(中央读片评估玻璃体混浊≥2级改善或激素减至<10 mg/天)两组差异无统计学意义(46.1% vs 30.0%,P=0.2354),但研究者评估的次要分析及基线玻璃体混浊≥2级亚组的混浊改善、总体最佳矫正视力提升均显著优于安慰剂。

要点

  • 主要终点按中央读片评估未达统计学显著(46.1% vs 30.0%,P=0.2354)。
  • 研究者评估的次要分析中sarilumab组显著更优(64.0% vs 35.0%,P=0.0372)。
  • 基线玻璃体混浊≥2级眼亚组混浊改善显著更优,总体视力提升也更明显。

核心结论

  • 皮下sarilumab可能对眼后段非感染性葡萄膜炎有临床获益,尤其在葡萄膜炎性黄斑水肿眼。

研究设计与样本

  • 每2周皮下注射sarilumab 200 mg或安慰剂,治疗16周。
  • 主要终点为第16周玻璃体混浊(Miami量表)≥2级改善或全身糖皮质激素减至<10 mg/天,基于中央读片中心评估。

主要发现

  • 第16周主要终点比例sarilumab组46.1% vs 安慰剂组30.0%(P=0.2354,中央读片评估)。
  • 研究者评估玻璃体混浊时,主要终点比例64.0% vs 35.0%(P=0.0372)。
  • 基线玻璃体混浊≥2级亚组平均混浊改善:中央读片-2.1(n=11)vs -1.7(n=3),P=0.0255;研究者评估-2.5(n=19)vs -1.2(n=11),P=0.0170。
  • 总体人群平均最佳矫正视力提升8.9 vs 3.6字母(P=0.0333);基线中央亚区厚度(CST)≥300 μm亚组12.2(n=13)vs 2.1(n=7)字母(P=0.0517)。
  • 总体人群CST变化-46.8 vs +2.6 μm(P=0.0683);基线CST≥300 μm亚组-112.5(n=13)vs -1.8(n=6)μm(P=0.1317)。

关键数值与推荐

  • 主要终点定义:第16周玻璃体混浊≥2级改善或泼尼松龙(或等效)剂量<10 mg/天。
  • 最常见眼部不良事件:葡萄膜炎加重(安慰剂0例,sarilumab 3例)和视网膜浸润(安慰剂1例,sarilumab 2例)。

临床怎么用

  • 对眼后段非感染性葡萄膜炎,尤其合并葡萄膜炎性黄斑水肿者,sarilumab可能提供临床获益。
  • 主要终点未达统计学显著,需结合研究者评估及亚组结果谨慎解读,等待进一步研究确认。

局限性

  • 主要终点基于中央读片评估未达统计学显著。
  • 部分视力与CST亚组比较的P值未达0.05。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess efficacy and safety of sarilumab, a human anti-interleukin-6 receptor antibody, for treatment of posterior segment noninfectious uveitis (NIU). DESIGN: Randomized, double-masked, placebo-controlled, phase 2 study. PARTICIPANTS: Fifty-eight patients (eyes) with noninfectious intermediate, posterior, or panuveitis. METHODS: Eyes received treatment every 2 weeks for 16 weeks with subcutaneous sarilumab 200 mg or placebo. MAIN OUTCOME MEASURES: The primary end point was the proportion of patients with ≥2-step reduction in vitreous haze (VH) on the Miami scale or with a reduction of systemic corticosteroids (prednisolone or equivalent) to a dose of <10 mg/day at week 16. Primary end point was based on VH evaluation by a central reading center. Investigator evaluation of VH was a prespecified, planned secondary analysis. RESULTS: At week 16, proportion of patients taking sarilumab or placebo with ≥2-step reduction in VH or corticosteroid dose <10 mg/day was 46.1% vs. 30.0% (P = 0.2354) based on central reading center assessment of VH and 64.0% vs. 35.0% (P = 0.0372) based on investigator assessment of VH, respectively. In the subgroup of eyes with VH grade ≥2 at baseline, the mean VH reduction from baseline to week 16 was significantly greater with sarilumab vs. placebo regardless of assessment by the central reading center (-2.1 [n = 11] vs. -1.7 [n = 3], respectively; P = 0.0255) or investigator (-2.5 [n = 19] vs. -1.2 [n = 11], respectively; P = 0.0170). The mean best-corrected visual acuity gain from baseline to week 16 was greater with sarilumab vs. placebo in the overall population (8.9 vs. 3.6 letters, respectively; P = 0.0333) and in the subgroup of eyes with central subfield thickness (CST) ≥300 μm at baseline (12.2 [n = 13] vs. 2.1 [n = 7] letters, respectively; P = 0.0517). Corresponding changes in CST were -46.8 vs. +2.6 μm (P = 0.0683) in the overall population and -112.5 [n = 13] vs. -1.8 [n = 6] μm (P = 0.1317) in the subgroup of eyes with CST ≥300 μm at baseline, respectively. The most common ocular adverse events were worsening of uveitis (0 [placebo] and 3 [sarilumab] patients) and retinal infiltrates (1 [placebo] and 2 [sarilumab] patients). CONCLUSIONS: Subcutaneous sarilumab may provide clinical benefits in the management of NIU of the posterior segment, especially in eyes with uveitic macular edema.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study. Ophthalmology. 2018. PMID: 30316888. doi:10.1016/j.ophtha.2018.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。